Biotech
BioNTech
BioNTech raises $325M Follow-on Offering at $45B valuation
$325M
Total Raised
Follow-on Offering
Latest Round
2008
Founded
5000+
Employees
An der Goldgrube 12, Mainz 55131, Germany
1 min read
Quick Facts
Valuation
$45B
Latest Round Size
$325M
Latest Round Date
July 2024
BioNTech: Follow-on Offering Funding Round
BioNTech has successfully raised $325M in Follow-on Offering funding, reaching a valuation of $45B.
Company Overview
Immunotherapy and mRNA vaccines
Funding Details
The Follow-on Offering round was led by Strüngmann Family Office, with participation from MIG, Salvia, AT Impf, Pfizer.
Company Information
- Headquarters: An der Goldgrube 12, Mainz 55131, Germany
- Founded: 2008
- Employees: 5000+
- Category: Biotech
Investment
BioNTech plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Strüngmann Family Office: Verified investor in Follow-on Offering
- MIG: Verified investor in Follow-on Offering
- Salvia: Verified investor in Follow-on Offering
- AT Impf: Verified investor in Follow-on Offering
- Pfizer: Verified investor in Follow-on Offering
Key Investors
Strüngmann Family Office
Lead Investor
Verified investor in Follow-on Offering
MIG
Investor
Verified investor in Follow-on Offering
Salvia
Investor
Verified investor in Follow-on Offering
AT Impf
Investor
Verified investor in Follow-on Offering
Pfizer
Investor
Verified investor in Follow-on Offering
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M